Rett Syndrome Research Trust
8
2
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
60%
3 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
The Rett Syndrome Global Registry
Role: lead
Validating Innovative Biosensors for Rett Autonomic Symptom Tracking
Role: lead
ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME
Role: lead
A Study to Evaluate Ketamine for the Treatment of Rett Syndrome
Role: lead
Development of the ORCA Communication Measure for Rett Syndrome
Role: lead
Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin
Role: collaborator
Pharmacological Treatment of Rett Syndrome With Statins
Role: collaborator
Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
Role: collaborator
All 8 trials loaded